SL Science (SLBT)
Develops licensed immune-cell therapies alongside Taiwan exosome and hair-care products.
Something off on this page? Send us feedback.
Sells exosome-based cosmetics and hair-care products in Taiwan while developing preclinical CD-19 Armed-T and donor-derived gamma delta T-cell therapies through licensed technology and external collaborators; commercial revenue still comes from the legacy portfolio.
Operates Exosome Products in Taiwan, including bovine-milk-derived exosome concentrate, skin-care products, and tangerine-extract hair and scalp-care products. CD-19 Armed-T Products target blood cancers, while GDT cell therapy Products use donor-derived gamma delta T cells for pancreatic cancer and glioblastoma; both programs remain preclinical.
Develops the therapeutic programs through licensed technology, external manufacturing, and academic and clinical collaborations rather than a fully integrated model. Commercial revenue comes from the legacy cosmetic and plant-extract portfolio, which management intends to phase out as cell therapies advance. Therapeutic development depends on licensed rights, clinical-grade material and IND-enabling toxicology; no candidate has an IND, human-trial record, or FDA approval.
Company facts
No analyst consensus on record.
Not reported.
Not reported.
No dividends on record.
No ownership filings on record for this listing.
560.76M company shares as of Aug 21, 2026 · holders as of their latest filing
Insider tradesForm 4
No open-market trades in the last 12 months.
- Gilead Sciences
Approved CD19 CAR-T option for B-cell blood cancers.
- Novartis (ADR)
Approved CD19 CAR-T franchise in B-cell leukemia and lymphoma.
- Bristol-Myers Squibb
Personalized CD19 CAR-T for a broad range of B-cell cancers.
- IN8bio
Gamma-delta programs include a clinical glioblastoma candidate.
- Adicet Bio
Allogeneic gamma-delta CAR-T platform for cancer and autoimmunity.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SL Science | $1.68 | 0.00% | $964.5M | — | — | — | — |
| Gilead Sciences | $152.73 | +0.04% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Novartis (ADR) | $141.28 | +0.01% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Bristol-Myers Squibb | $62.31 | +0.10% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| IN8bio | $1.13 | 0.00% | $10.2M | — | — | — | — |
| Adicet Bio | $9.31 | +2.42% | $83.5M | — | — | — | — |
| Median | 17.5 | 15.0 | 4.8 | +5.7% |